Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study

Publication date: September 2018Source: The Lancet Haematology, Volume 5, Issue 9Author(s): Hervé Tilly, Franck Morschhauser, Olivier Casasnovas, Thierry Jo Molina, Pierre Feugier, Steven Le Gouill, Corinne Haioun, Olivier Tournilhac, Reda Bouabdallah, Jean Gabarre, Thierry Lamy, José Cabeçadas, Stéphanie Becker, Fabrice Jardin, Nicolas Mounier, Gilles Salles, Lymphoma Study AssociationSummaryBackgroundImmunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. The combination of lenalidomide and rituximab has shown high efficacy in relapsed or refractory and untreated follicular lymphoma. We aimed to evaluate the safety and activity of the combination of lenalidomide and R-CHOP (R2-CHOP) in previously untreated patients with high burden follicular lymphoma.MethodsThis single-arm, open-label, multicentre, phase 2 trial was done in 16 hospitals in France, all of which were Lymphoma Study Association (LYSA) sites. Eligible patients were aged 18–70 years and had previously untreated CD20-positive follicular lymphoma of grade 1, 2, or 3a; at least one high tumour burden criterion according to Groupe d'Etude des Lymphomes Folliculaires criteria; an Eastern Cooperative Oncology Group performance status score of 2 or less; and a minimum life expectancy of more than 3 months. Patients received induction therapy with six cycles of R2-CHOP every 3 weeks (one cycle involved stand...
Source: The Lancet Haematology - Category: Hematology Source Type: research